Abstract
Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Keywords: Efalizumab, psoriasis, treatment, biologics
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Efalizumab
Volume: 6 Issue: 3
Author(s): Ekin Savk
Affiliation:
Keywords: Efalizumab, psoriasis, treatment, biologics
Abstract: Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Export Options
About this article
Cite this article as:
Ekin Savk , Efalizumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368292
DOI https://dx.doi.org/10.2174/187152307781368292 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Recent Developments in Phytosterol Recovery from Oil Deodorizer Distillates
Current Nutrition & Food Science MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry Anticoagulant Therapy During Pregnancy for Maternal and Fetal Acquired and Inherited Thrombophilia
Current Medicinal Chemistry Coal Mine Dust Lung Disease: The Silent Coal Mining Disaster
Current Respiratory Medicine Reviews Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Use of Diuretics in Women for Management of Hypertension
Current Hypertension Reviews The LDL-Receptor and its Molecular Properties: From Theory to Novel Biochemical and Pharmacological Approaches in Reducing LDL-cholesterol
Current Medicinal Chemistry Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Current Drug Safety Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design An Efficient Machine Learning Model for Prediction of Acute Myocardial Infarction
Recent Advances in Computer Science and Communications